Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.
NovoCure's Capital Expenditure for the
three
months ended in Mar. 2022 was $-5.09 Mil. Its Operating Income for the
three
months ended in Mar. 2022 was $-0.81 Mil.
GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.
NovoCure Capex-to-Operating-Income Historical Data
The historical data trend for NovoCure's Capex-to-Operating-Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Capex-to-Operating-Income
-
-
-
0.49
-
NovoCure Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Capex-to-Operating-Income
-
-
-
-
-
Competitive Comparison
For the Medical Instruments & Supplies subindustry, NovoCure's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Capex-to-Operating-Income Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Capex-to-Operating-Income distribution charts can be found below:
* The bar in red indicates where NovoCure's Capex-to-Operating-Income falls into.
NovoCure Capex-to-Operating-Income Calculation
NovoCure's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.
NovoCure Capex-to-Operating-Income Related Terms
Thank you for viewing the detailed overview of NovoCure's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.09(2.89%) Volume: 109,188 11:40AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:NVCR has been successfully added to your 
